Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
4.425
-0.385 (-8.00%)
Mar 31, 2025, 1:19 PM EDT - Market open
Y-mAbs Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Y-mAbs Therapeutics stock have an average target of 18.73, with a low estimate of 7.00 and a high estimate of 26. The average target predicts an increase of 323.28% from the current stock price of 4.43.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Y-mAbs Therapeutics stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 10 | 10 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $12 | Strong Buy | Maintains | $22 → $12 | +171.19% | Mar 21, 2025 |
| B of A Securities | B of A Securities | Hold Maintains $14 → $12 | Hold | Maintains | $14 → $12 | +171.19% | Mar 5, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $21 → $18 | Strong Buy | Maintains | $21 → $18 | +306.78% | Mar 5, 2025 |
| Morgan Stanley | Morgan Stanley | Sell Maintains $11 → $7 | Sell | Maintains | $11 → $7 | +58.19% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +397.18% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
105.28M
from 87.69M
Increased by 20.07%
Revenue Next Year
114.50M
from 105.28M
Increased by 8.76%
EPS This Year
-1.00
from -0.67
EPS Next Year
-0.99
from -1.00
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 124.4M | 136.3M | 146.3M | ||
| Avg | 105.3M | 114.5M | 122.9M | ||
| Low | 82.6M | 89.6M | 89.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 41.8% | 29.5% | 27.7% | ||
| Avg | 20.1% | 8.8% | 7.4% | ||
| Low | -5.8% | -14.9% | -21.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.85 | -0.49 | -0.75 | ||
| Avg | -1.00 | -0.99 | -1.07 | ||
| Low | -1.14 | -1.15 | -1.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.